At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 266 enrolled
Drug / intervention
fostamatinib +1 moredrug
Likely dose
fostamatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating fostamatinib and placebo for Rheumatoid Arthritis. Completed, enrolled 266 participants across 56 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Czechia, Germany, Poland, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedMar 27, 2012
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.3 years ago
Interventions
fostamatinibdrug
fostamatinib 100 mg twice daily
placebodrug
placebo